Calyx Medical Imaging said it participated in the pivotal phase II clinical trial of Iovance Biotherapeutic's Amtagvi (lifileucel), a cell therapy for adults with unresectable or metastatic melanoma who have relapsed on other front-line therapy.
Calyx contributed to the design and implementation of the imaging components of the trial. As a result, 60 investigative sites were able to capture patient CT, MRI, PET, and skin photography images in compliance with the image review protocol, according to the firm.
